Quoin Pharmaceuticals: Bullish Outlook on Netherton Syndrome Treatment and Regulatory Advantages

Quoin Pharmaceuticals receives a Buy rating from analyst Naz Rahman of Maxim Group due to its promising developments in treating Netherton Syndrome (NS) with lead product QRX003. Positive Phase 3 trial results and FDA Rare Pediatric Disease Designation, as well as Orphan Drug Designation from the EMA, support potential approval and market success. The potential for a Pediatric Review Voucher adds to the financial attractiveness of the stock, justifying the Buy rating. QNRX's price has increased by 2419.35% over the past six months.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has received a Buy rating from analyst Naz Rahman of Maxim Group, citing the company's promising developments in treating Netherton Syndrome (NS) with its lead product QRX003. The positive Phase 3 trial results and FDA Rare Pediatric Disease Designation, as well as Orphan Drug Designation from the EMA, support potential approval and market success for QRX003. The potential for a Pediatric Review Voucher adds to the financial attractiveness of the stock, justifying the Buy rating.

QRX003 is currently being tested in two pivotal registrational clinical studies across the U.S., Europe, and the Middle East. The studies aim to recruit between 12 to 16 subjects each, with full recruitment targeted for early to mid Q1 2026. The company anticipates releasing topline data from both studies early next year and is targeting an NDA filing in 2H 2026. Quoin plans to self-commercialize QRX003 in the U.S., Western Europe, and Japan, with nine commercial partnerships covering 61 additional countries to support global access of the product once approved.

The company has also discontinued the development of QRX007 for NS and has decided not to advance QRX004 as a potential treatment for Epidermolysis Bullosa (EB). Quoin is focusing its resources on high-potential opportunities, such as its Peeling Skin Syndrome (PSS) clinical study and topical rapamycin program.

Quoin Pharmaceuticals' stock price has increased by 2419.35% over the past six months, reflecting investor optimism about the company's pipeline and the potential market success of QRX003.

References:
[1] https://www.globenewswire.com/news-release/2025/07/29/3123220/0/en/Quoin-Pharmaceuticals-Provides-Product-Portfolio-Update.html
[2] https://www.globenewswire.com/news-release/2025/07/31/3124998/0/en/Quoin-Pharmaceuticals-to-Announce-Second-Quarter-2025-Financial-Results-on-Thursday-August-7-2025.html